Avalon GloboCare (US:ALBT) Globenewswire·2025-08-28 13:00Core Viewpoint - Avalon GloboCare Corp. is launching the KetoAir™ breathalyzer device in the UK, expanding its market presence following its U.S. launch, targeting individuals on ketogenic diets for health management [1][3]. Product Overview - KetoAir™ is a handheld breathalyzer that measures breath acetone concentration (BrAce), indicating fat metabolism and ketosis, and is registered as a Class I medical device with the U.S. FDA [2][4]. - The device is designed for users pursuing ketogenic diets for weight loss, athletic performance, or therapeutic purposes, utilizing advanced nano-sensor technology for real-time metabolic insights [2][3]. Market Strategy - The launch in the UK is seen as a strategic move to capitalize on the growing adoption of ketogenic and low-carb diets, positioning KetoAir™ as a tool to help individuals achieve their health and wellness goals [3]. - The product will be available for purchase starting September 1, 2025, through the dedicated website [1][3]. Company Background - Avalon GloboCare Corp. focuses on developing precision diagnostic consumer products and advancing intellectual property in cellular therapy, with plans to explore additional diagnostic uses for the breathalyzer technology [4].